Literature DB >> 10491201

Type I beta-turn conformation is important for biological activity of the melanocyte-stimulating hormone analogues.

S Z Li1, J H Lee, W Lee, C J Yoon, J H Baik, S K Lim.   

Abstract

In order to define which structure of alpha-melanocyte-stimulating hormone (MSH) analogues plays a critical role for ligand-receptor interaction and selectivity, we analysed receptor-binding and cAMP-generating activity in Chinese hamster ovary cell lines stably transfected with rMC3R and hMC4R, as well as the NMR structures of chemically synthesized alpha-MSH analogues. Compared with [Ahx4]alpha-MSH, the linear MTII designated as alpha-MSH-ND revealed a preference for the MC4R, whereas its IC50 and EC50 values were comparable to those of MTII reported previously. Truncation of Ahx4 and Asp5 of alpha-MSH-ND remarkably decreased the receptor-binding and cAMP-generating activity. Meanwhile, maximum cAMP-generating activity was observed at a higher concentration (10(-5) M) of alpha-MSH-ND(6-10), and MC4R preference was changed into MC3R preference. In contrast, [Gln6]alpha-MSH-ND(6-10) lost its cAMP-generating activity almost completely, even though it bound to both receptors. Whereas the solution conformation of alpha-MSH-ND revealed a stable type I beta-turn structure, [Gln6]alpha-MSH-ND(6-10) revealed a tight gamma-turn composed of Gln6-D-Phe7-Arg8. Replacement of the His6 residue of alpha-MSH-ND by Gln, Asn, Arg or Lys decreased not only the receptor binding, but also the cAMP-generating activity in both the MC3R and the MC4R. The structure of [Gln6]alpha-MSH-ND exhibited a stable type I' beta-turn comprising Asp5, Gln6, D-Phe7 and Arg8. [Lys6]alpha-MSH-ND showed a greatly reduced binding affinity and cAMP-generating activity with the loss of MC4R selectivity. In NMR studies, [Lys6]alpha-MSH-ND also demonstrated a gamma-turn conformation around Lys6-DPhe7-Arg8. From the above results, we conclude that a type I beta-turn conformation comprising the residues Asp5-His6-(D-Phe7)-Arg8 was important for receptor binding and activation, as well as the selectivity of MSH analogues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491201     DOI: 10.1046/j.1432-1327.1999.00763.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

Review 1.  Exploring privileged structures: the combinatorial synthesis of cyclic peptides.

Authors:  Douglas A Horton; Gregory T Bourne; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

Review 2.  Exploring privileged structures: the combinatorial synthesis of cyclic peptides.

Authors:  Douglas A Horton; Gregory T Bourne; Mark L Smythe
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

3.  Topological side-chain classification of beta-turns: ideal motifs for peptidomimetic development.

Authors:  Tran Trung Tran; Jim McKie; Wim D F Meutermans; Gregory T Bourne; Peter R Andrews; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2005-11-23       Impact factor: 3.686

4.  Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.

Authors:  Alexander V Mayorov; Minying Cai; Kevin B Chandler; Ravil R Petrov; April R Van Scoy; Zerui Yu; Dustin K Tanaka; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

5.  Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).

Authors:  Anamika Singh; Marvin Dirain; Rachel Witek; James R Rocca; Arthur S Edison; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2013-03-25       Impact factor: 7.446

6.  A deep dense inception network for protein beta-turn prediction.

Authors:  Chao Fang; Yi Shang; Dong Xu
Journal:  Proteins       Date:  2019-07-23

7.  Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold.

Authors:  Steven Ballet; Alexander V Mayorov; Minying Cai; Dagmara Tymecka; Kevin B Chandler; Erin S Palmer; Karolien Van Rompaey; Aleksandra Misicka; Dirk Tourwé; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2007-02-09       Impact factor: 2.823

8.  Interactions of the melanocortin-4 receptor with the peptide agonist NDP-MSH.

Authors:  Kathryn L Chapman; Gemma K Kinsella; Alan Cox; Dan Donnelly; John B C Findlay
Journal:  J Mol Biol       Date:  2010-06-19       Impact factor: 5.469

9.  AHTPDB: a comprehensive platform for analysis and presentation of antihypertensive peptides.

Authors:  Ravi Kumar; Kumardeep Chaudhary; Minakshi Sharma; Gandharva Nagpal; Jagat Singh Chauhan; Sandeep Singh; Ankur Gautam; Gajendra P S Raghava
Journal:  Nucleic Acids Res       Date:  2014-11-11       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.